Psychiatric Bulletin (2008) 32: 358-359. doi: 10.1192/pb.32.9.358b
© 2008 The Royal College of Psychiatrists
This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by McIlhinney, S.
Right arrow Articles by Smith, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by McIlhinney, S.
Right arrow Articles by Smith, M.

Correspondence

Depot risperidone, hyperprolactinaemia and prolactin-associated side-effects

Selwyn McIlhinney, Consultant Psychiatrist

*Whangarei Hospital, Whangarei, Northland, New Zealand, email: smcilhinney1{at}waitrose.com

Michael Smith, Consultant Psychiatrist

Dykebar Hospital, Paisley, UK

Declaration of interest

None.

Hyperprolactinaemia is a significant adverse effect of antipsychotic treatment and is particularly associated with dopamine-blocking agents like risperidone. Hyperprolactinaemia may cause menstrual disturbance, galactorrhoea, impotence and reduced libido. These problems impair the quality of life and contribute to non-adherence to medication (Maguire, 2002). Chronic hyperprolactinaemia has been associated with osteoporosis (Naidoo et al, 2003).

Depot risperidone is an injectable, slow-release formulation whose prolactin-inducing properties may differ from oral risperidone. Only one previous trial assessed hyperprolactinaemia associated with the use of depot risperidone in routine clinical care (Bushe & Shaw, 2007).

In a pilot study in Renfrewshire, Scotland, we identified 37 individuals who were taking depot risperidone. Twelve individuals had medical conditions or took other drugs that may have influenced the level of prolactin and thus were excluded from our study. The remaining 25 individuals had the level of prolactin measured and they completed a questionnaire about prolactin-related side-effects. Ten individuals refused to take part in the study and it was completed by 15 participants (9 men and 6 women, mean age 48 years, mean duration of treatment with depot risperidone 15.4 months).

In 12 participants the level of prolactin has risen, with 3 individuals having levels more than four times the upper limit of normal. Only 4 participants with hyperprolactinaemia complained of any prolactin-related symptoms. One person complained of prolactin-related symptoms despite having a normal prolactin level.

The prevalence of hyperprolactinaemia in this study was 80% compared with 53% reported by Bushe & Shaw (2007).

Most individuals taking depot risperidone will have hyperprolactinaemia and reported symptoms are an unreliable guide to prolactin levels. Further study is required to inform decisions about the clinical management of this patient group.

References

  1. BUSHE, C. & SHAW, M. (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. Journal of Psychopharmacology, 21, 768 -773.[Abstract/Free Full Text]
  2. MAGUIRE, G. A. (2002) Prolactin elevation with antipsychotic medication: mechanisms of action and clinical consequences. Journal of Clinical Psychiatry, 63 (suppl. 4), 56 -62.
  3. NAIDOO, U., GOFF, D. C. & KLIBANSKI, A. (2003) Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology, 28, 97-108.[CrossRef][Medline]




This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by McIlhinney, S.
Right arrow Articles by Smith, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by McIlhinney, S.
Right arrow Articles by Smith, M.